$50 Million

Clearside Biomedical

Initial Public Offering

Lead Left Bookrunner, June 2016

Clearside Biomedical
Clearside BioMedical is a late-stage clinical biopharmaceutical company developing drug therapies to treat blinding diseases of the eye. Its product candidates are injected into the suprachoroidal space, or SCS, using its proprietary SCS Microinjector. Its most advanced product candidates, CLS-1001 and CLS-1003, consist of SCS injections of Zuprata, its proprietary corticosteroid triamcinolone acetonide. CLS-1003 is being developed for the treatment of macular edema associated with retinal vein occlusion (RVO). CLS-1001 is being developed for the treatment of macular edema associated with non-infectious uveitis. The Company is also developing CLS-1002 for the treatment of wet AMD. Its lead compound, axitinib, has anti-VEGF and anti-PDGF activity, which will be administered by SCS injection.